Market Failure and the Poverty of New Drugs in Maternal Health

A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs).

[1]  Joanna Owens.  2006 drug approvals: finding the niche , 2007, Nature Reviews Drug Discovery.

[2]  D. Paintin.  Effective Care in Pregnancy and Childbirth , 1990, British journal of obstetrics and gynaecology.

[3]  P. Peppin.  Manufacturing uncertainty: adverse effects of drug development for women. , 2003, International journal of law and psychiatry.

[4]  J M Friedman,et al.  Teratogenicity of Recently Introduced Medications in Human Pregnancy , 2002, Obstetrics and gynecology.

[5]  J. Martin,et al.  Births: preliminary data for 2005. , 2006, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[6]  J. Cairns,et al.  Maternal and Perinatal Conditions , 2006 .

[7]  L. Say,et al.  Maternal mortality in 2005 : estimates developed by WHO, UNICEF, UNFPA and the World Bank , 2008 .

[8]  I. Choonara,et al.  Unlicensed and off label drug use in paediatric wards: prospective study , 1998, BMJ.

[9]  J. Guzman,et al.  The New Landscape of Neglected Disease Drug Development , 2005 .

[10]  N. Fisk,et al.  The case for tocolysis in threatened preterm labour , 2003, BJOG : an international journal of obstetrics and gynaecology.

[11]  D. Reith,et al.  Pediatric Licensing Status and the Availability of Suitable Formulations for New Medical Entities Approved in the United States Between 1998 and 2002 , 2006, Journal of clinical pharmacology.

[12]  D. Cutler.  The demise of the blockbuster? , 2007, The New England journal of medicine.

[13]  Heidi L. Williams,et al.  Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. , 2007, Health economics.

[14]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[15]  C. Giaquinto,et al.  Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years , 2006, European Journal of Clinical Pharmacology.

[16]  A. Oxman,et al.  System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe , 2005, BMJ : British Medical Journal.

[17]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[18]  J. Thornton.  The drugs we deserve , 2003, BJOG : an international journal of obstetrics and gynaecology.

[19]  H. Odendaal,et al.  Do women with pre-eclampsia and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial , 2002 .

[20]  H. Nisell,et al.  Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour , 2003, BJOG : an international journal of obstetrics and gynaecology.

[21]  R. Horton,et al.  Research challenges to improve maternal and child survival , 2007, The Lancet.

[22]  J. Lawn,et al.  Stillbirth rates: delivering estimates in 190 countries , 2006, The Lancet.

[23]  Contributions from M. Walpole.  The Millennium Development Goals Report , 2008 .

[24]  N. Fisk,et al.  Litigation and prescribing drugs for unlicensed indications , 1993, The Lancet.

[25]  Dominique L. Monnet,et al.  Priority Medicines for Europe and the World , 2005 .

[26]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[27]  M. Lapeyre-Mestre,et al.  Prescription of drugs during pregnancy in France , 2000, The Lancet.

[28]  E. Beghi,et al.  The epidemiology of ALS and the role of population-based registries. , 2006, Biochimica et biophysica acta.

[29]  B. Pécoul,et al.  Access to essential drugs in poor countries: a lost battle? , 1999, JAMA.